HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sakai, K. Articles by Clemmons, D. R. Search for Related Content PubMed PubMed Citation Articles by Sakai, K. Articles by Clemmons, D. R. Social Bookmarking                What's this?

Physiological Differences in Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Phosphorylation in IGFBP-1 Transgenic Mice

From the Departments of Medicine (K.S., D.R.C.) and Pediatrics (A.J.D.E.), University of North Carolina School of Medicine, Chapel Hill, NC; and the Department of Medicine (L.J.M.), University of Manitoba, Winnipeg, Manitoba, Canada.

Address correspondence and reprint requests to David R. Clemmons, MD, Building 7170, 6111 Thurston Bowles, School of Medicine, Division of Endocrinology, University of North Carolina, Chapel Hill, NC 27599-7170. E-mail: endo{at}med.unc.edu .

Insulin-like growth factor binding protein (IGFBP)-1 has been shown to alter cellular responses to insulin-like growth factor 1 (IGF-1). Human IGFBP-1 undergoes serine phosphorylation, and this enhances both its affinity for IGF-1 by six- to eightfold and its capacity to inhibit IGF-1 actions. To investigate the physiological role of IGFBP-1 in vivo, transgenic mice have been generated using either the human IGFBP-1 or rat IGFBP-1 transgene. Both lines of mice expressed high concentrations of IGFBP-1 in serum and tissues; however, human IGFBP-1 transgenic mice did not show glucose intolerance and exhibited no significant intrauterine growth retardation, whereas rat IGFBP-1 transgenic mice showed fasting hyperglycemia and intrauterine growth restriction. The aim of this study was to investigate the physiological differences in the phosphorylation state of human IGFBP-1 and rat IGFBP-1 in these transgenic mice. The phosphorylation status of IGFBP-1 in transgenic mouse serum was analyzed by nondenaturing PAGE. Almost all of the IGFBP-1 in serum from the human IGFBP-1 transgenic mice was present as a nonphosphorylated form. Most of the rat IGFBP-1 in the serum of the mice expressing the rat IGFBP-1 was phosphorylated. Immunoprecipitation showed that mouse hepatoma (Hepa 1-6) cells (exposed to [³²P]H₃PO₄) secrete ³²P-labeled IGFBP-1. When the human IGFBP-1 transgene was transfected into Hepa 1-6 cells, all of the IGFBP-1 was secreted in the nonphosphorylated form. However, when the rat IGFBP-1 transgene was transfected into these cells, phosphorylated forms of IGFBP-1 were secreted. To confirm this result, the mouse hepatoma cell protein kinase was partially purified. This kinase activity phosphorylated mouse and rat IGFBP-1 in vitro, but it did not phosphorylate human IGFBP-1. Scatchard analysis showed that the affinity of phosphorylated rat IGFBP-1 for IGF-1 was 3.9-fold higher than that of nonphosphorylated human IGFBP-1. We conclude that the mouse IGFBP-1 kinase activity cannot phosphorylate human IGFBP-1, whereas it can phosphorylate rat IGFBP-1. The phosphorylation state of human IGFBP-1 may account for part of the phenotypic differences noted in the two studies of transgenic mice, and it is an important determinant of the capacity of human IGFBP-1 to inhibit IGF-1 actions in vivo.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				C. S. Watson, P. Bialek, M. Anzo, J. Khosravi, S.-P. Yee, and V. K. M. Han Elevated Circulating Insulin-Like Growth Factor Binding Protein-1 Is Sufficient to Cause Fetal Growth Restriction Endocrinology, March 1, 2006; 147(3): 1175 - 1186. [Abstract] [Full Text] [PDF]

				M. Kabir-Salmani, Y. Shimizu, K. Sakai, and M. Iwashita Posttranslational modifications of decidual IGFBP-1 by steroid hormones in vitro Mol. Hum. Reprod., September 1, 2005; 11(9): 667 - 671. [Abstract] [Full Text] [PDF]

				J. Beattie, K. Phillips, J. H Shand, M. Szymanowska, D. J Flint, and G. J Allan Molecular recognition characteristics in the insulin-like growth factor (IGF)-insulin-like growth factor binding protein -3/5 (IGFBP-3/5) heparin axis J. Mol. Endocrinol., February 1, 2005; 34(1): 163 - 175. [Abstract] [Full Text] [PDF]

				V. Cingel-Ristic, B. F. Schrijvers, A. K. van Vliet, R. Rasch, V. K. M. Han, S. L. S. Drop, and A. Flyvbjerg Kidney Growth in Normal and Diabetic Mice Is Not Affected by Human Insulin-Like Growth Factor Binding Protein-1 Administration Experimental Biology and Medicine, February 1, 2005; 230(2): 135 - 143. [Abstract] [Full Text] [PDF]

				J.-G. Scharf, F. Dombrowski, R. Novosyadlyy, C. Eisenbach, I. Demori, B. Kubler, and T. Braulke Insulin-Like Growth Factor (IGF)-Binding Protein-1 Is Highly Induced during Acute Carbon Tetrachloride Liver Injury and Potentiates the IGF-I-Stimulated Activation of Rat Hepatic Stellate Cells Endocrinology, July 1, 2004; 145(7): 3463 - 3472. [Abstract] [Full Text] [PDF]

				C. H. Lang, T. C. Vary, and R. A. Frost Acute in Vivo Elevation of Insulin-Like Growth Factor (IGF) Binding Protein-1 Decreases Plasma Free IGF-I and Muscle Protein Synthesis Endocrinology, September 1, 2003; 144(9): 3922 - 3933. [Abstract] [Full Text] [PDF]

				K. Sakai, H. B. Lowman, and D. R. Clemmons Increases in Free, Unbound Insulin-like Growth Factor I Enhance Insulin Responsiveness in Human Hepatoma G2 Cells in Culture J. Biol. Chem., April 12, 2002; 277(16): 13620 - 13627. [Abstract] [Full Text] [PDF]